As these new treatments become available, we want to make sure that they are delivered through the NHS to people with type 1 diabetes as quickly as possible.
To achieve this we provide evidence and patient input to the National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN). These are the two organisations that evaluate which medicines should be prescribed and paid for by the NHS, and provide guidelines to doctors about best treatment practices.
As well as providing input for NICE and SIGN treatment reviews ourselves, we work with industry and researchers to ensure that they are producing appropriate evidence for these two bodies. We also make sure that patients’ views are represented by asking people with type 1 diabetes to take part in reviews, and we help people with type 1 are kept up to date about the best and latest treatment options so that they can discuss them with their healthcare team.